MAP2K7 and melanoma: For example, the type-III MEK kinase inhibitor, Cobimetinib (IC50 0.9 nM), overcomes the resistance induced by the BRAF V600E mutation seen in melanoma by inhibiting MEK, which is downstream of BRAF in the BRAF/MEK/ERK pathway [16].